Floatz logo

VEMURAFENIB

Refractory Non-Hodgkin Lymphoma

OHSU Knight Cancer InstituteSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Refractory Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Lyell Immunopharma, Inc.
Phase 3BB
Olaparib
OHSU Knight Cancer Institute
Phase 2BB
Vesanoid
Rita Assi
Phase 2B
cd19/22 cart
The First Affiliated Hospital of Soochow University
Phase 2B
Pyrotinib
The First Affiliated Hospital of Soochow University
Phase 2B

View all 16 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →